Covovax™
COVID-19
Approved/CommercialWHO EUL-approved
Key Facts
About Novavax
Novavax is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel vaccines to prevent serious infectious diseases. Its core technology platform combines recombinant nanoparticle antigens with its patented saponin-based Matrix-M™ adjuvant to stimulate robust immune responses. The company achieved a major milestone with the global authorization of its COVID-19 vaccine and is now advancing a diversified pipeline targeting respiratory viruses. Novavax's strategic direction involves expanding the utility of its platform, pursuing combination vaccines, and establishing its commercial presence.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| Remdesivir (Veklury) | Gilead Sciences | Approved |
| mRNA-1273 (Spikevax) | Moderna | Approved |
| Investigational Oral COVID-19 Antiviral | Shionogi | Clinical |
| ZyCoV-D | Zydus Lifesciences | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| SARS-CoV-2 Neutralizing Antibodies | Adaptive Biotechnologies | Discovery |
| LY-CoV555 (Bamlanivimab) | AbCellera | Emergency Use Authorization (Past) |
| ARCT-154 (Bivalent) | Arcturus Therapeutics | Phase 1/2 |
| LUNAR-COV19 (ARCT-021) | Arcturus Therapeutics | Phase 1/2 |
| Paxlovid (Nirmatrelvir) Manufacturing Enzyme | Codexis | Commercial |